Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

NTLA

Intellia Therapeutics Inc

Jan 08 • 04:00PM ET

10.52

+0.39 3.85 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK XBI VTI ARKG IWM VB VBK VXF IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.27	Insider Own	4.93%	Shs Outstand	115.79M	Perf Week	17.02%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-3.63	Insider Trans	1.22%	Shs Float	110.12M	Perf Month	11.44%
Enterprise Value	805.46M	PEG	-	EPS next Q	-0.96	Inst Own	86.35%	Short Float	36.85%	Perf Quarter	-57.01%
Income	-445.81M	P/S	21.18	EPS this Y	23.91%	Inst Trans	4.97%	Short Ratio	5.82	Perf Half Y	-13.49%
Sales	57.53M	P/B	1.63	EPS next Y	9.24%	ROA	-42.49%	Short Interest	40.58M	Perf YTD	17.02%
Book/sh	6.46	P/C	2.38	EPS next 5Y	29.78%	ROE	-52.11%	52W High	28.25 -62.76%	Perf Year	-17.81%
Cash/sh	4.41	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-54.43%	52W Low	5.90 78.31%	Perf 3Y	-69.64%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	78.27%	Volatility	6.25% 5.18%	Perf 5Y	-80.66%
Dividend TTM	-	EV/Sales	14.00	EPS Y/Y TTM	21.66%	Oper. Margin	-820.86%	ATR (14)	0.62	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.21	Sales Y/Y TTM	33.52%	Profit Margin	-774.94%	RSI (14)	59.38	Recom	2.22
Dividend Gr. 3/5Y	- -	Current Ratio	6.21	EPS Q/Q	31.56%	SMA20	12.27%	Beta	2.10	Target Price	22.12
Payout	-	Debt/Eq	0.13	Sales Q/Q	51.27%	SMA50	8.16%	Rel Volume	0.96	Prev Close	10.13
Employees	403	LT Debt/Eq	0.09	Earnings	Nov 06 AMC	SMA200	-7.23%	Avg Volume	6.97M	Price	10.52
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.48% -0.94%	Trades		Volume	6,703,406	Change	3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight	$5
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$14
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39

Show Previous Ratings

Jan-07-26 07:30AM	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
Jan-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 01:33PM	Cathie Wood shells out $1.3 million on biotech stock (TheStreet)
09:32AM	Loading…
09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 07:35AM	What Makes Intellia Therapeutics (NTLA) an Interesting Investment? (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 01:41PM	Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory (Insider Monkey) +7.51%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks) +5.52%
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-25-25 08:39AM	Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress (Insider Monkey)
10:19AM	Loading…
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data (Insider Monkey)
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:00AM	Should You Buy the Dip in Intellia Therapeutics Stock? (Barchart) -8.64%
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly) -6.78%
Nov-11-25 07:30AM	Is This Beaten-Down Cathie Wood Stock Still a Buy? (Barchart)
Nov-10-25 03:17PM	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
01:19PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
05:13PM	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.73%
04:14PM	Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies (Investor's Business Daily)
10:55AM	Intellia Therapeutics Says a Patient Died in Gene Editing Trial (Barrons.com)
09:56AM	Loading…
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:45AM	2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street (Motley Fool)
Nov-06-25 05:20PM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.21%
04:00PM	Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
Nov-05-25 11:35AM	VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? (Zacks) +11.23%
11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
Nov-04-25 10:41AM	Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint (Zacks) -6.66%
10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
Nov-02-25 09:25AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% (Motley Fool)
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -6.52%
06:54AM	FDA places formal hold on two Intellia CRISPR trials (BioPharma Dive)
Oct-29-25 06:05PM	Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates (Zacks) -6.02%
Oct-28-25 12:43PM	CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause (GuruFocus.com) -5.61%
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 12:03PM	Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial (Barrons.com) -42.23%
08:25AM	Intellia stock tumbles after pausing gene therapy trials on safety concerns (Investing.com)
08:00AM	Intellia pauses two CRISPR drug studies after safety scare (BioPharma Dive)
07:30AM	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Oct-21-25 12:56PM	Intellia (NTLA) Soars 13% to Fresh High (Insider Monkey)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks) +13.05%
09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
04:59AM	Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' (Insider Monkey)
Oct-08-25 12:00PM	Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know (Zacks) +19.72%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
09:55AM	Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know (Zacks)
09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:45AM	1 Stock Up by 63% This Year That Could Double, According to Wall Street (Motley Fool)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
Oct-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 10:47AM	Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought (Motley Fool) +8.63%
Sep-25-25 01:57PM	Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug (Benzinga) -6.48%
09:52AM	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-22-25 09:09AM	Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus (Zacks) +10.71%
07:30AM	Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 07:30AM	Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema (GlobeNewswire) +29.81%
Sep-11-25 03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Sep-02-25 03:46PM	Cathie Wood Pours $4 Million Into This High-Growth Biotech Stock (GuruFocus.com)
09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
10:59AM	Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? (Barchart)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-11-25 07:43AM	Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus (Zacks)
Aug-08-25 11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks) -5.85%
06:05AM	Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 \| Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9 (GlobeNewswire)
03:55AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Aug-07-25 08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-01-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks) -5.60%
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Jul-30-25 09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-28-25 08:41AM	Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus (Zacks)
Jul-15-25 04:27PM	Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (MarketBeat)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-08-25 12:54PM	The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. (Barchart) +8.49%
Jul-07-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEONARD JOHN M	President and CEO	Jan 05 '26	Sale	9.21	34,146	314,485	1,013,339	Jan 07 04:05 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Jan 05 '26	Sale	9.21	8,508	78,359	98,533	Jan 07 04:05 PM
BASTA JAMES	EVP, General Counsel	Jan 05 '26	Sale	9.21	10,397	95,756	101,528	Jan 07 04:05 PM
Cohen Fred E	Director	Jan 05 '26	Buy	9.35	150,000	1,402,500	207,453	Jan 07 04:05 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 05 '26	Sale	9.21	11,903	109,627	121,249	Jan 07 04:04 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 05 '26	Sale	9.21	9,515	87,633	87,118	Jan 07 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jan 05 '26	Sale	9.21	6,379	58,751	99,683	Jan 07 04:02 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 05 '26	Sale	9.21	2,989	27,529	52,277	Jan 07 04:01 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Option Exercise	6.83	49,959	341,220	1,127,074	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 12 '25	Option Exercise	6.83	8,557	58,444	1,047,485	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Sale	9.49	88,146	836,384	1,038,928	Dec 12 04:09 PM
LEONARD JOHN M	Officer	Dec 11 '25	Proposed Sale	9.33	88,146	822,402		Dec 11 04:11 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Oct 01 '25	Sale	17.38	31	539	105,184	Oct 03 05:13 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 01 '25	Sale	17.38	1,871	32,518	55,266	Oct 03 05:13 PM
CHASE WILLIAM J	Director	Aug 20 '25	Buy	10.03	100,000	1,003,000	134,693	Aug 22 04:30 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 23 '25	Sale	14.02	7,462	104,617	106,062	Jul 25 04:05 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience